Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Hires Key Personnel, Plans to Expand Lab Staff for R&D in 2019 and Issues Stock Options

  • LXRP is putting its growth plan into effect, adding a new corporate controller, a head of its legal division and more office staff; in 2019, it will also be increasing its lab personnel
  • As a result of the latest positions created, the company is issuing 240,000 new stock options with an exercise price of $1.06 that will vest as to 80,000 per year until April 15, 2021
  • LXRP has a growing IP portfolio of 10 patents granted in the U.S. and Australia; it has filed for more than 50 patents worldwide across 10 patent families

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP), a drug delivery platform innovator, has announced aggressive growth plans, including the addition of key personnel, a special focus on its lab R&D activities in 2019 and the issue of new stock options.

It has added a new corporate controller, a head of its legal division and additional office staff. In addition, LXRP anticipates adding more lab personnel next year as it intensifies its R&D activities. As a result of the latest positions created, LXRP is issuing 240,000 new stock options with an exercise price of $1.06 that will vest as to 80,000 per year until April 15, 2021, it announced.

Based in British Columbia, Canada, LXRP is a biotechnology company that out-licenses its disruptive delivery technology that promotes healthier ingestion methods. LXRP holds a patent for oral delivery of all cannabinoids and has a growing IP portfolio. DehydraTECH is its proprietary absorption technology platform.

LXRP has received $110,000 from exercised warrants (http://cnw.fm/uTx6Y). The company has also received for exercise a total of 250,000 previously granted warrants with an exercise price of $0.44. Proceeds will be used for general corporate purposes, the company said. No commissions or placement fees were paid related to the funds received from these warrants. LXRP added that the warrants were exercised by third parties, not officers or directors of the company.

For more information, visit the company’s website at www.LexariaBioscience.com

More from CannabisNewsWire

About CBDWire

CBDWire (CBDW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CBDNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CBDW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CBDW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CBDW brings its clients unparalleled visibility, recognition and brand awareness. CBDW is where news, content and information converge.

CBDWire is at the epicenter of the Cannabis Revolution.

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.cbdwire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

CBDWire (CBDW)
Denver, Colorado
cbdwire.com
303.498.7722 Office
Editor@CBDWire.com

Archives

Select A Month

CBDWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Doge Coin

Dogecoin

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 303.498.7722